Detail akcie VITA 34 online

Business Summary: FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, FamiCord AG revenues increased 10% to EUR66.4M. Net income applicable to common stockholders excluding extraordinary items totaled EUR1.5M vs. loss of EUR239K. Revenues reflect Subgroup PBKM segment increase of 19% to EUR35M. Net Income reflects Net impairment on financial and contract decrease of 43% to EUR888K (expense), Financial income increase of 52% to EUR1.9M (income).